These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 10816721)

  • 1. [Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients].
    Hébert M
    Presse Med; 2000 Apr; 29(14):790-2. PubMed ID: 10816721
    [No Abstract]   [Full Text] [Related]  

  • 2. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ramipril on cardiovascular events in high-risk patients.
    O'Rourke MF; Nichols WW
    N Engl J Med; 2000 Jul; 343(1):64-5; author reply 66. PubMed ID: 10896544
    [No Abstract]   [Full Text] [Related]  

  • 4. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].
    Scheen AJ
    Rev Med Liege; 2000 Feb; 55(2):121-4. PubMed ID: 10769584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood-pressure reduction and cardiovascular risk in HOPE study.
    Sleight P; Yusuf S; Pogue J; Tsuyuki R; Diaz R; Probstfield J;
    Lancet; 2001 Dec 22-29; 358(9299):2130-1. PubMed ID: 11784631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular protection: a breakthrough for high-risk patients?
    Ferrari R
    J Hypertens Suppl; 2009 Jul; 27(5):S37-40. PubMed ID: 19587554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ADVANCE trial.
    Procopiou M
    Lancet; 2008 Jan; 371(9606):25; author reply 26. PubMed ID: 18177767
    [No Abstract]   [Full Text] [Related]  

  • 10. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Böhm M; Baumhäkel M; Mahfoud F; Werner C
    Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.
    Kramer CM; Ferrari VA; Rogers WJ; Theobald TM; Nance ML; Axel L; Reichek N
    J Am Coll Cardiol; 1996 Jan; 27(1):211-7. PubMed ID: 8522697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Sleight P
    J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The reduction of cardiovascular risk with ramipril].
    Vanuzzo D
    Ital Heart J Suppl; 2000 May; 1(5):713-4. PubMed ID: 10834142
    [No Abstract]   [Full Text] [Related]  

  • 14. [Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].
    Bischoff A
    Internist (Berl); 2000 Jan; 41(1):A24-7. PubMed ID: 10712083
    [No Abstract]   [Full Text] [Related]  

  • 15. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
    Sica DA
    Curr Opin Nephrol Hypertens; 2001 Sep; 10(5):597-601. PubMed ID: 11496052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should you take an ACE inhibitor?
    Johns Hopkins Med Lett Health After 50; 2000 Mar; 12(1):1-2. PubMed ID: 10740441
    [No Abstract]   [Full Text] [Related]  

  • 17. A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
    Ritz E; Dahlöf B
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S1-2. PubMed ID: 18580859
    [No Abstract]   [Full Text] [Related]  

  • 18. A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.
    Comarow A
    US News World Rep; 1999 Nov; 127(20):76. PubMed ID: 10623306
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of ramipril on cardiovascular events in high-risk patients.
    Weinsaft JW
    N Engl J Med; 2000 Jul; 343(1):64; author reply 66. PubMed ID: 10896543
    [No Abstract]   [Full Text] [Related]  

  • 20. ACE inhibitors to prevent cardiovascular events in high-risk patients.
    VandeKieft GK
    J Fam Pract; 2000 Apr; 49(4):373-4. PubMed ID: 10778846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.